Alpex Pharma Profile
Key Indicators
- Authorised Capital ₹ 3.00 Cr
as on 16-11-2024
- Paid Up Capital ₹ 3.00 Cr
as on 16-11-2024
- Company Age 2 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 8.23 Cr
as on 16-11-2024
- Satisfied Charges ₹ 6.00 Cr
as on 16-11-2024
About Alpex Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.00 Cr and a paid-up capital of Rs 3.00 Cr.
The company currently has active open charges totaling ₹8.23 Cr. The company has closed loans amounting to ₹6.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Sanjay Mittal, Shubham Mittal, and Karamjeet Singh serve as directors at the Company.
- CIN/LLPIN
U24299HR2022PTC102687
- Company No.
102687
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Apr 2022
- Date of AGM
28 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Panchkula, Haryana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Alpex Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjay Mittal  | Director | 08-Apr-2022 | Current |
| Shubham Mittal | Director | 08-Apr-2022 | Current |
| Karamjeet Singh | Additional Director | 24-Aug-2024 | Current |
Financial Performance of Alpex Pharma.
Alpex Pharma Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Alpex Pharma?
In 2023, Alpex Pharma had a public holding of 24.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Pgi Pharmacy Private LimitedActive 2 months 3 daysSanjay Mittal and Shubham Mittal are mutual person
- Hotel Wonder Hill Private LimitedActive 2 years 5 months
Sanjay Mittal and Shubham Mittal are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 30 Sep 2024 | ₹8.23 Cr | Open |
State Bank Of India Creation Date: 15 Jun 2023 | ₹6.00 Cr | Satisfied |
How Many Employees Work at Alpex Pharma?
Unlock and access historical data on people associated with Alpex Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Alpex Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Alpex Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
